Vanguard Group Inc. Has $162.88 Million Stock Holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Vanguard Group Inc. raised its stake in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 36.4% during the fourth quarter, Holdings Channel reports. The firm owned 4,733,609 shares of the company’s stock after buying an additional 1,262,362 shares during the period. Vanguard Group Inc. owned about 0.08% of Harmony Biosciences worth $162,883,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. HighTower Advisors LLC grew its position in Harmony Biosciences by 364.0% in the third quarter. HighTower Advisors LLC now owns 79,961 shares of the company’s stock valued at $3,199,000 after acquiring an additional 62,729 shares during the period. XTX Topco Ltd acquired a new stake in shares of Harmony Biosciences in the 3rd quarter valued at $451,000. Y Intercept Hong Kong Ltd bought a new stake in shares of Harmony Biosciences in the 3rd quarter worth about $280,000. Barclays PLC increased its position in shares of Harmony Biosciences by 110.9% during the 3rd quarter. Barclays PLC now owns 76,862 shares of the company’s stock worth $3,074,000 after purchasing an additional 40,416 shares in the last quarter. Finally, Franklin Resources Inc. lifted its holdings in Harmony Biosciences by 6.1% during the 3rd quarter. Franklin Resources Inc. now owns 29,773 shares of the company’s stock valued at $1,191,000 after purchasing an additional 1,720 shares during the last quarter. 86.23% of the stock is currently owned by institutional investors.

Harmony Biosciences Stock Performance

Harmony Biosciences stock opened at $29.26 on Monday. The company has a current ratio of 3.24, a quick ratio of 3.20 and a debt-to-equity ratio of 0.28. The company has a market cap of $1.68 billion, a PE ratio of 13.87, a PEG ratio of 0.47 and a beta of 0.80. The company’s 50-day moving average is $35.30 and its two-hundred day moving average is $35.23. Harmony Biosciences Holdings, Inc. has a 1 year low of $28.14 and a 1 year high of $41.61.

Harmony Biosciences (NASDAQ:HRMY) last released its earnings results on Tuesday, February 25th. The company reported $0.85 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.11. The firm had revenue of $201.30 million for the quarter, compared to analyst estimates of $201.25 million. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. The company’s quarterly revenue was up 19.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.45 earnings per share. Equities analysts anticipate that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current year.

Insider Activity at Harmony Biosciences

In other Harmony Biosciences news, CEO Jeffrey M. Dayno sold 19,293 shares of the stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $40.13, for a total value of $774,228.09. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Jeffrey Dierks sold 1,629 shares of the firm’s stock in a transaction dated Monday, January 27th. The stock was sold at an average price of $38.02, for a total value of $61,934.58. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 72,452 shares of company stock worth $2,831,679. 30.80% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several analysts have weighed in on the stock. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Harmony Biosciences in a research note on Tuesday, February 11th. They set a “buy” rating and a $55.00 price objective on the stock. HC Wainwright decreased their price target on Harmony Biosciences from $75.00 to $70.00 and set a “buy” rating on the stock in a research report on Thursday, February 27th. Mizuho lifted their price objective on Harmony Biosciences from $42.00 to $44.00 and gave the company an “outperform” rating in a research report on Tuesday, March 18th. Finally, Needham & Company LLC restated a “buy” rating and set a $50.00 target price on shares of Harmony Biosciences in a report on Tuesday, February 25th. Nine equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Harmony Biosciences currently has a consensus rating of “Buy” and a consensus price target of $53.33.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.